Flu Season Helps BioMerieux's FilmArray Offset Immunoassay Weakness
We plan to await BioMerieux’s full year-end results before we adjust our model, but we may change our fair value estimate as we re-evaluate the firm’s tax rate implications following the recent law implemented in the United States. BioMerieux’s fourth-quarter sales preview of 8.9% organic constant-currency growth mostly matches our expectations, even though currency effects continue to pressure reported growth. We think the shares look overvalued, though we still appreciate the firm’s narrow eco...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.